WallStSmart

Lineage, Inc. Common Stock (LINE)vsRexford Industrial Realty Inc (REXR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 438% more annual revenue ($5.36B vs $995.92M). REXR leads profitability with a 23.3% profit margin vs -2.7%. REXR earns a higher WallStSmart Score of 63/100 (C+).

LINE

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

REXR

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 6.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.54
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

REXRUndervalued (+71.5%)

Margin of Safety

+71.5%

Fair Value

$131.72

Current Price

$34.07

$97.65 discount

UndervaluedFair: $131.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

REXR4 strengths · Avg: 9.3/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Operating MarginProfitability
41.5%10/10

Strong operational efficiency at 41.5%

Profit MarginProfitability
23.3%9/10

Keeps 23 of every $100 in revenue as profit

EPS GrowthGrowth
28.0%8/10

Earnings expanding 28.0% YoY

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

REXR4 concerns · Avg: 3.8/10
PEG RatioValuation
1.884/10

Expensive relative to growth rate

P/E RatioValuation
37.3x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Return on EquityProfitability
2.8%3/10

ROE of 2.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : REXR

The strongest argument for REXR centers on Price/Book, Operating Margin, Profit Margin. Profitability is solid with margins at 23.3% and operating margin at 41.5%.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : REXR

The primary concerns for REXR are PEG Ratio, P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while REXR is a declining play — different risk/reward profiles.

LINE is growing revenue faster at 0.4% — sustainability is the question.

REXR generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

REXR scores higher overall (63/100 vs 34/100), backed by strong 23.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.

Visit Website →

Rexford Industrial Realty Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

Rexford Industrial, a real estate investment trust that focuses on owning and operating industrial properties in the infill markets of Southern California, owns 232 properties with approximately 27.

Want to dig deeper into these stocks?